Futura Medical plc (AIM: FUM), a provider of consumer healthcare products, announced on Wednesday that it has successfully completed its WSD4000 Home User study, which demonstrated positive outcomes for the treatment of sexual dysfunction in women. The study, involving 67 women, showed a significant improvement in sexual function after four weeks of use, with many participants reporting increased vaginal lubrication, genital sensation, pleasure and overall satisfaction.
The study's results indicated a strong user response, with 57% of women using the product more frequently than the recommended minimum. Among those with sexual dysfunction, notable improvements were observed in arousal, lubrication, orgasm, satisfaction and discomfort (pain).
Following these promising results, Futura's Board has recommended proceeding with an Early Feasibility Study in H1 2025. This will further refine the product's methodology and assess its efficacy in a broader population.
WSD4000 is a topical treatment designed to address common symptoms of sexual dysfunction in women, such as lack of arousal, lubrication and desire. There is currently no regulatory-approved, over-the-counter topical treatment for women's sexual dysfunction. Market research indicates a significant opportunity, as 40%-50% of women experience some form of sexual dysfunction, with 60% of those affected reporting symptoms in the last year. Despite this, only a quarter seek professional help, and many see little improvement over time.
Futura Medical's portfolio also includes Eroxon, a clinically proven topical treatment for erectile dysfunction (ED), with strong market presence through distribution partners like Haleon and Cooper Consumer Health.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval